英特集团：收购华通医药股权获反垄断审查通过

Core Viewpoint - The announcement indicates that the subsidiary, Yingtai Pharmaceutical, is participating in the acquisition of 100% equity of Huadong Pharmaceutical for a transaction price of 369 million yuan, with regulatory approval received for the deal [1] Group 1: Acquisition Details - Yingtai Pharmaceutical is bidding for 100% equity of Huadong Pharmaceutical at a price of 369 million yuan [1] - The acquisition has received a non-prohibition decision from the State Administration for Market Regulation, allowing the transaction to proceed [1] - The transaction parties can implement the concentration immediately and will follow up with necessary business registration changes [1] Group 2: Regulatory Approval - The company has received the "Non-Prohibition Decision on Concentration of Operators" from the National Market Supervision Administration [1] - This decision signifies that there are no antitrust concerns regarding the acquisition, facilitating the completion of the deal [1] - The company will fulfill its information disclosure obligations based on the progress of the transaction [1]